Table 1 Neutrophil count for suspending treatment with each anticancer agent
| Anticancer agent | Neutrophil count (/μl) |
|---|---|
| 5-fluorouracil | <1,000 |
| Bendamustine | <1,000 |
| Carboplatin | <1,000 |
| Cisplatin | <1,000 |
| Cyclophosphamide | <1,000 |
| Cytarabine | <1,000 |
| Docetaxel | <1,000 |
| Doxorubicin | <1,000 |
| Etoposide | <1,000 |
| Gemucitabine | <1,000 |
| Ifosfamide | <1,000 |
| Irinotecan | <1,500 |
| Methotorexate | <1,000 |
| Oxaliplatin | <1,500 |
| Paclitaxel (tri weekly) | <2,000 |
| Paclitaxel (weekly) | <1,500 |
| Pirarubicin | <1,000 |
| Pemetrexed | <1,500 |
| Vinorelbine | <2,000 |